Beihai Kangcheng-B (01228) announced that CAN008 in patients newly diagnosed with glioblastoma based on treatment...
According to the Zhitong Finance App, Beihai Kangcheng-B (01228) announced that according to top-line data from the CAN008 phase II clinical trial for newly diagnosed glioblastoma patients, in patients receiving standard treatment with temozolomide and radiotherapy, CAN008 provides no additional benefit compared to placebo in terms of progression-free survival or overall survival.
After careful consideration, the company decided to discontinue the development and further testing of CAN008 in the field of glioblastoma. The Group will optimize R&D pipelines, improve efficiency and preserve cash. The funds saved by discontinuing the development of CAN008 in the field of glioblastoma will be used to accelerate commercialization of the two approved products, Harith and Melirebe, and clinical development of the Group's other products, including but not limited to CAN106 (whose ongoing phase 1b paroxysmal nocturnal hemoglobinuria study has shown positive initial results), CAN103 (which is currently undergoing registration tests on patients with Gaucher disease), and selective gene therapy programs. The cessation of development of CAN008 in the field of glioblastoma will not have a significant impact on the Group's performance.